Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 48,502 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 48,502 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $30.05, for a total transaction of $1,457,485.10. Following the transaction, the president owned 842,307 shares in the company, valued at approximately $25,311,325.35. This trade represents a 5.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences Price Performance

Shares of NYSE:RCUS opened at $28.12 on Tuesday. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19. The company has a market cap of $3.54 billion, a P/E ratio of -8.84 and a beta of 0.80. Arcus Biosciences, Inc. has a 52 week low of $8.84 and a 52 week high of $31.74. The company has a 50-day moving average price of $25.98 and a 200 day moving average price of $23.53.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The business had revenue of $17.00 million for the quarter, compared to analyst estimates of $29.48 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The business’s revenue for the quarter was down 39.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.14) EPS. Research analysts predict that Arcus Biosciences, Inc. will post -3.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on RCUS. Truist Financial began coverage on Arcus Biosciences in a research report on Monday, May 18th. They issued a “buy” rating and a $35.00 price objective for the company. Lifesci Capital assumed coverage on shares of Arcus Biosciences in a research report on Thursday, June 4th. They set an “outperform” rating and a $46.00 target price on the stock. The Goldman Sachs Group upped their price target on shares of Arcus Biosciences from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Leerink Partners set a $47.00 price target on shares of Arcus Biosciences in a report on Monday, April 20th. Finally, Wall Street Zen cut shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Arcus Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $35.10.

Institutional Trading of Arcus Biosciences

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC increased its position in shares of Arcus Biosciences by 253.9% in the first quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock valued at $714,000 after buying an additional 65,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Arcus Biosciences by 10.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock worth $297,000 after buying an additional 3,565 shares during the last quarter. Millennium Management LLC boosted its position in shares of Arcus Biosciences by 29.2% in the 1st quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock worth $9,378,000 after buying an additional 270,253 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Arcus Biosciences by 106.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock worth $7,177,000 after buying an additional 470,755 shares in the last quarter. Finally, Strs Ohio acquired a new stake in Arcus Biosciences in the 1st quarter valued at about $67,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.